The Latest Cardiac and Vascular News
BETonMACE did not meet the primary endpoint Apabetalone development to continue to be advanced by the Company based on BETonMACE results Primary results to be presented during a late-breaking science session at AHA 2019 Apabetalone demonstrated tolerability and safety Resverlogix to host investor webcast and conference call on Monday, September […]
CALGARY, Alberta, Sept. 27, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) today announces that it has issued a 10% secured convertible debenture in the principal amount of US$12 million (the “Debenture”) to a wholly-owned subsidiary of ORI Star Fund LP (“ORI” or the “Fund”). The […]
CALGARY, Alberta, Sept. 23, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the Late Breaking Science submission, regarding the primary results of the BETonMACE trial, has been accepted by the American Heart Association (“AHA”) for presentation during Scientific Sessions 2019 held in Philadelphia, Pennsylvania. The trial results […]
Top-line results projected to be available on or about September 30, 2019 Number of MACE increases from 250 to greater than 275 CALGARY, Alberta, Sept. 16, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported […]
CALGARY, Alberta, July 08, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company’s event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking another important step towards trial completion. Given the remaining steps […]
CALGARY, Alberta, March 27, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed a ninth planned safety review for the Company’s Phase 3, BETonMACE trial for high-risk cardiovascular disease patients and recommended the study continue without modification. The […]
CALGARY, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone downregulates factors and pathways associated with vascular calcification” in Atherosclerosis, the official peer-reviewed scientific journal of the European Atherosclerosis Society. “Apabetalone and its unique mechanism […]
CALGARY, Alberta, Oct. 22, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology (ASN) Kidney Week 2018, Clinical Trials on Alzheimer’s Disease (CTAD) 2018 and the American Heart Association (AHA) Scientific Sessions 2018. Through […]
CALGARY, Alberta, Aug. 30, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today it has closed a private placement of approximately 10.4 million equity units at a price of $2.50 per unit for gross proceeds of approximately $26 million (US$20 million), based on an agreed discount […]
CALGARY, Alberta, Aug. 22, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announced it is supporting a satellite symposium on August 25th, 2018, at the European Society of Cardiology Congress 2018 in Munich, Germany, titled: LDL-c: Done Deal, Next Epigenetics? Satellite Symposium Agenda 15:30 – 15:35 (local […]
